David A Sallman
Overview
Explore the profile of David A Sallman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
2248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Garciaz S, Dumas P, Bertoli S, Sallman D, Decroocq J, Belhabri A, et al.
Am J Hematol
. 2024 Jun;
99(10):1870-1876.
PMID: 38899566
Venetoclax-azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In the VIALE-A study, treatment was given until progression but there are no data on its optimal duration...
12.
Efficace F, Buckstein R, Abel G, Giesinger J, Fenaux P, Bewersdorf J, et al.
Hemasphere
. 2024 May;
8(5):e69.
PMID: 38774655
Notable treatment advances have been made in recent years for patients with myelodysplastic syndromes/neoplasms (MDS), and several new drugs are under development. For example, the emerging availability of oral MDS...
13.
Santini V, Stahl M, Sallman D
Am Soc Clin Oncol Educ Book
. 2024 May;
44(3):e432650.
PMID: 38768424
mutations are found in 5%-10% of de novo myelodysplastic syndrome (MDS) and AML cases. By contrast, in therapy related MDS and AML, mutations in are found in up to 30%-40%...
14.
Tentori C, Zhao L, Tinterri B, Strange K, Zoldan K, Dimopoulos K, et al.
Hemasphere
. 2024 May;
8(5):e64.
PMID: 38756352
Advancements in comprehending myelodysplastic neoplasms (MDS) have unfolded significantly in recent years, elucidating a myriad of cellular and molecular underpinnings integral to disease progression. While molecular inclusions into prognostic models...
15.
DiNardo C, Roboz G, Watts J, Madanat Y, Prince G, Baratam P, et al.
Blood Adv
. 2024 Apr;
8(15):4209-4220.
PMID: 38640348
Ivosidenib is a first-in-class mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor with efficacy and tolerability in patients with advanced mIDH1 hematologic malignancies, leading to approval in frontline and relapsed/refractory (R/R) mIDH1...
16.
Jain A, Gesiotto Q, Ball S, Nodzon L, Rodriguez A, Chan O, et al.
Ann Hematol
. 2024 Apr;
103(6):1941-1945.
PMID: 38634915
Dasatinib is one of the second generation tyrosine kinase inhibitors (TKI) which is approved for the treatment of patients with chronic phase CML (CP-CML) both in the front line and...
17.
Ionescu F, David J, Ravichandran A, Sallman D, Sweet K, Komrokji R, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Mar;
24(6):400-406.
PMID: 38429222
Background: Hypomethylating agent + venetoclax is an effective frontline combination for acute myeloid leukemia, but its efficacy and safety in post-allogeneic hematopoietic cell transplant (alloHCT) relapse remain underexplored. Outcomes have...
18.
Jain A, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, et al.
Haematologica
. 2024 Feb;
109(7):2157-2164.
PMID: 38299605
The patterns of low-risk myelodysplastic syndrome (MDS) progression and the clinical and molecular features of those patterns have not been well described. We divided our low-risk (LR) MDS patients (N=1,914)...
19.
Rajakumaraswamy N, Gandhi M, Wei A, Sallman D, Daver N, Mo S, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Jan;
24(4):260-268.e2.
PMID: 38216397
Introduction: Azacitidine (AZA) is an approved frontline therapy for higher-risk myelodysplastic syndromes (HR-MDS); however, poor survival denotes unmet needs to increase depth/duration of response (DOR). Methods: This retrospective study with...
20.
Tefferi A, Fleti F, Chan O, Al Ali N, Al-Kali A, Begna K, et al.
Br J Haematol
. 2023 Dec;
204(4):1243-1248.
PMID: 38083865
Among 210 patients with myelodysplastic syndromes (MDSs) with del(5q), molecular information was available at diagnosis or at least 3 months before leukaemic transformation in 146 cases. Multivariate analysis identified therapy-related...